Key Inclusion Criteria:

        1. Participants with histologically or cytologically confirmed advanced or metastatic solid
        tumor who have experienced disease progression during or after at least 1 line of prior
        systemic anticancer therapy, or for whom treatment is not available or not
        tolerated/acceptable to the participants. In addition, participants must meet the following
        eligibility criteria for the corresponding phase of the study:

        a. Phase 1a: Participants with a known mutation status and tumor harboring an oncogenic
        B-RAF or K-RAS/N-RAS mutation, or any other MAPK pathway aberrations. In Phase 1a, the
        study recruitment will be limited to approximately one third (1/3) participants with
        K-RAS/N-RAS mutation, and among these participants the study recruitment will be limited to
        approximately one third (1/3) colorectal cancer (CRC) or pancreatic participants.

        a. Phase 1b: participants must have a known mutation status and meet one of the following
        criteria according to the group they are enrolled into:

          1. Group 1: participants with solid tumors with non-V600 B-RAF mutations including RAF
             fusions,; or

          2. Group 2: participants with B-RAF V600 mutated melanoma or non-small cell lung cancer
             (NSCLC), and have progressed on a B-RAF-inhibitor and/or MEK-inhibitor resistant
             tumors (i.e., mitogen-activated protein kinase/extracellular signal regulated kinase)
             inhibitor resistant tumors.

        2. Participants must provide tumor tissue sample (archival tumor tissue or agree to a fresh
        tumor biopsy) for mutation and biomarkers analysis 3. Participants must have measurable
        disease as defined per RECIST v1.1. 4. Eastern Cooperative Oncology Group performance
        status of ≤1 at Screening. 5. Adequate hematologic and organ function, as indicated by the
        following laboratory values, prior to Cycle 1 Day 1

        Key Exclusion Criteria:

          1. Participants receiving cancer therapy (chemotherapy or other systemic anticancer
             therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1.

          2. All participants who have received prior systemic anticancer treatment within the
             following time frames will be excluded:

               1. Cyclical chemotherapy within a period of time that is shorter than the cycle
                  length used for that treatment (i.e., 6 weeks for nitrosourea, mitomycin C) prior
                  to Cycle 1 Day 1; and

               2. Biologic therapy (i.e., antibodies), continuous or intermittent small-molecule
                  therapies, or any other investigational agents within a period of 5 times the
                  half-life of the agent or ≤4 weeks (whichever is shorter) prior to Cycle 1 Day 1.

          3. History or presence of gastrointestinal disease or other condition known to interfere
             with the absorption, distribution, metabolism, or excretion of drugs.

          4. Leptomeningeal disease or untreated/unstable brain metastasis except participants with
             previously treated brain metastasis who are radiologically stable (imaging evidence
             required), asymptomatic and have been off steroids and antiseizure medications for
             longer than 28 days prior to Cycle 1 Day 1 are permitted.

          5. Any unstable, preexisting major medical condition that in the opinion of the
             investigator contraindicates the use of an IMP, including known human immunodeficiency
             virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
             Participants who are hepatitis B surface antigen (HBsAg) positive or HCV antibody
             positive at Screening may be enrolled only if HBV DNA titers <500 IU/mL or negative
             HCV RNA polymerase chain reaction test, respectively.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.